Home / Resources / Regulatory update

Regulatory update · 4 min read

Written Confirmation for APIs Imported into the EU: A Practical Overview

Active Pharmaceutical Ingredients (APIs) are essential to the quality, safety, and effectiveness of medicinal products. When APIs are manufactured outside the European Union and imported into the EU, organizations must understand the applicable regulatory requirements and ensure that the supply chain is appropriately controlled.

One important requirement under Article 46b of Directive 2001/83/EC is the written confirmation associated with certain APIs imported from third countries. This confirmation provides assurance about the GMP standards applied to the manufacturing site and the oversight exercised by the exporting country's competent authority.

Understanding the requirement helps API manufacturers, importers, distributors, and marketing authorisation holders maintain appropriate documentation and reduce the risk of supply-chain compliance gaps.

1. What Is a Written Confirmation?

A written confirmation is a document issued by the competent authority of an exporting third country, confirming specified aspects of GMP compliance and regulatory oversight for the API manufacturing site.

Under Article 46b, the confirmation addresses whether:

  • The GMP standards applicable to the manufacturing site are at least equivalent to the relevant EU GMP standards.
  • The manufacturing site is subject to regular, strict, and transparent controls, including repeated and unannounced inspections, with effective enforcement.
  • Information about relevant GMP non-compliance findings is communicated to the EU without undue delay.

The written confirmation is a regulatory document. It should not be confused with a supplier's self-declaration, an audit report, a certificate of analysis, or a GMP certificate.

2. When Is It Required?

For APIs imported into the EU from third countries, Article 46b establishes conditions relating to GMP compliance and written confirmation.

However, the requirement is subject to specific provisions and exceptions. In particular, the written-confirmation requirement does not apply to countries included on the relevant list maintained under Article 111b. A limited waiver may also be possible in exceptional circumstances when the relevant legal conditions are met, including an inspection by a Member State competent authority and a compliant outcome.

Organizations should therefore verify the exporting country's current status and the applicable legal provisions rather than assuming that every API shipment follows the same documentation route.

3. What Should Importers and API Suppliers Verify?

A structured review should consider the following areas.

Manufacturing-site identity

Confirm that the documentation identifies the correct API manufacturing site and corresponds to the facility and activities involved in the supply chain. Pay attention to differences between a corporate address, a registered office, and the actual manufacturing location.

Regulatory authority and document validity

Verify that the document was issued by the appropriate competent authority. Review its date, scope, authenticity, and any conditions or limitations stated in the document. Where necessary, seek confirmation through official regulatory channels.

Country status and applicable exceptions

Check whether the exporting country is covered by the relevant EU list and whether any exception or waiver applies. Keep evidence of the assessment and the rationale for the regulatory route selected.

Supply-chain traceability

Ensure that the API's manufacturer, supplier, importer, and relevant intermediaries are correctly identified. Maintain traceable records linking the material received to the approved supplier and manufacturing source.

Supporting GMP evidence

Written confirmation should be considered alongside other applicable supplier-qualification and compliance evidence. Depending on the circumstances, this may include GMP status information, audit reports, quality agreements, supplier assessments, and relevant regulatory records.

A written confirmation does not replace all other obligations relating to API qualification, verification, or importation.

4. Documentation and Supply-Chain Controls

Organizations should establish documented procedures for obtaining, reviewing, retaining, and periodically verifying relevant regulatory documentation.

A practical process may include:

  • Identify the API manufacturer and the country in which the API is manufactured.
  • Determine which legal requirements and exceptions apply.
  • Obtain the relevant written confirmation where required.
  • Verify the document's authenticity, scope, and applicability.
  • Link the evidence to the approved supplier and material records.
  • Reassess the documentation when the manufacturer, site, country status, or applicable requirements change.
  • Escalate missing, inconsistent, or questionable documents through the quality system before making an unsupported compliance decision.

Procurement and supply-chain teams should coordinate with Quality Assurance and Regulatory Affairs so that commercial decisions do not bypass necessary quality or regulatory checks.

5. Common Issues to Watch For

Potential weaknesses include:

  • Written confirmation missing where it is required.
  • Documents that refer to a different site or manufacturer.
  • Unverified or outdated regulatory information.
  • Confusion between a written confirmation and a GMP certificate.
  • Inadequate evidence supporting the use of an exception.
  • Supplier records that do not clearly identify the actual manufacturing source.
  • Failure to reassess documentation after significant supply-chain changes.

These issues should be assessed according to their regulatory and quality impact. Any gaps should be addressed through documented review and appropriate escalation.

Conclusion

Written confirmation requirements form part of the EU's framework for controlling the importation of APIs from third countries. Effective compliance depends on understanding when the requirement applies, verifying the relevant documentation, and maintaining clear traceability throughout the supply chain.

A documented, risk-aware approach helps organizations support informed supplier qualification and import decisions while reducing avoidable regulatory uncertainty.

PharmaTrak supports pharmaceutical organizations through independent, evidence-based GxP audits that help assess supplier controls, identify compliance gaps, and strengthen quality oversight.

Regulatory note: This article is for general educational purposes and is not legal advice. Requirements and exceptions must be verified against the current consolidated version of Directive 2001/83/EC, relevant EU lists, applicable national requirements, and official regulatory guidance before making an import decision.

Discuss your audit requirements

Independent, evidence-based GxP audits from PharmaTrak.

Request an Audit